The stock has a 36-month beta value of 1.20. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DARE is 98.82M, and at present, short sellers hold a 0.24% of that float. On April 17, 2024, the average trading volume of DARE was 358.71K shares.
DARE) stock’s latest price update
Dare Bioscience Inc (NASDAQ: DARE)’s stock price has plunge by -36.19relation to previous closing price of 0.48. Nevertheless, the company has seen a -35.35% plunge in its stock price over the last five trading sessions. Seeking Alpha reported 2024-03-28 that Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript
DARE’s Market Performance
Dare Bioscience Inc (DARE) has seen a -35.35% fall in stock performance for the week, with a -39.33% decline in the past month and a -2.43% plunge in the past quarter. The volatility ratio for the week is 4.76%, and the volatility levels for the past 30 days are at 8.20% for DARE. The simple moving average for the past 20 days is -36.94% for DARE’s stock, with a -37.39% simple moving average for the past 200 days.
DARE Trading at -32.80% from the 50-Day Moving Average
After a stumble in the market that brought DARE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.87% of loss for the given period.
Volatility was left at 8.20%, however, over the last 30 days, the volatility rate increased by 4.76%, as shares sank -42.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.66% lower at present.
During the last 5 trading sessions, DARE fell by -38.38%, which changed the moving average for the period of 200-days by -67.60% in comparison to the 20-day moving average, which settled at $0.4799. In addition, Dare Bioscience Inc saw 0.13% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for DARE
Current profitability levels for the company are sitting at:
- -11.01 for the present operating margin
- 0.99 for the gross margin
The net margin for Dare Bioscience Inc stands at -10.62. The total capital return value is set at -38.56. Equity return is now at value -994.69, with -92.65 for asset returns.
Based on Dare Bioscience Inc (DARE), the company’s capital structure generated -6.59 points at debt to capital in total, while cash flow to debt ratio is standing at -8.87. The debt to equity ratio resting at -0.87. The interest coverage ratio of the stock is 90.89.
Currently, EBITDA for the company is -30.8 million with net debt to EBITDA at 0.17. When we switch over and look at the enterprise to sales, we see a ratio of 9.35. The receivables turnover for the company is 2.96for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.86.
Conclusion
To sum up, Dare Bioscience Inc (DARE) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
